ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Merck & Co. partners with Dewpoint for biological condensate drug discovery

by Ryan Cross
July 18, 2020 | APPEARED IN VOLUME 98, ISSUE 28

 

The Boston-based start-up Dewpoint Therapeutics has struck a partnership with Merck & Co. to develop drugs that treat HIV. Dewpoint is focused on developing new ways to drug biomolecular condensates, droplet-like structures of RNA, proteins, and other molecules inside cells that form through a physical process called liquid-liquid phase separation. The firm says these droplets hold secrets for new ways to make drugs for tough-to-treat and untreatable diseases. Dewpoint could receive up to $305 million in payments from Merck.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment